The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer

European Journal of Surgical Oncology

Volumn 33, Issue 8, 2007, Pages 961-966

  Clouth, B ^a   Chandrasekharan, S ^a   Inwang, R ^a   Smith, S ^a   Davidson, N ^a   Sauven, P ^a  

^a BROOMFIELD HOSPITAL   (United Kingdom)

Author keywords

Advanced; Breast cancer; Neoadjuvant therapy; Surgical management

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34548658801     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.12.006     Document Type: Article

References (31)

1. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
2. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
3. Powles T.J., Hickish T.F., Makris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 (1995) 547-552
4. van der Hage J., Van de Velde C., Julien J.-P., Tubiana-Hulin M., Vandervelden C., and Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19 (2001) 4224-4237
5. Kuerer H., Newman L., Smith T., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
6. Chatuverdi S., McLaren C., Schofield A.C., et al. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?. Breast Cancer Res Treat 93 (2005) 151-158
7. Guarneri V., Broglio K., Kau S.-W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 (2006) 1037-1044
8. Ring A., Webb A., Ashley S., et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?. J Clin Oncol 21 (2003) 4540-4545
9. Londero V., Bazzocchi M., Del Frate C., et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14 8 (2004 Aug) 1371-1379
10. Sachelari I., Grossbard M., Chadha M., Feldman S., Ghesani M., and Blum R. Primary systemic therapy of breast cancer. Oncologist 11 (2006) 574-589
11. Sauven P. The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer. Eur J Cancer 38 (2002) 2371-2374
12. Miller A., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
13. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc 185 (1958) 457-481
14. Miller K., McCaskill-Stevens W., Sisk J., et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17 (1999) 3033-3037
15. Smith I., Heys S., Hutcheon A., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 (2002) 1456-1466
16. Bear H., Anderson S., Brown A., et al. The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21 (2003) 4165-4174
17. Buzdar A., Singletary E., Theriault R., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17 (1999) 3412-3417
18. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 (2005) 2676-2685
19. Heys S.D., Sarkar T., and Hutcheon A.W. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90 (2005) 169-185
20. Schott A.F., Roubidoux M.A., Helvie M.A., et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92 (2005) 231-238
21. Chagpar A., Middleton L., Sahin A., et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243 (2006) 257-264
22. Nadeem R., Chagla L.S., Harris O., et al. Tumour localisation with a metal coil before the administration of neo-adjuvant chemotherapy. Breast 14 (2005) 403-407
23. Kaufmann M., von Minckwitz G., and Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14 (2005) 576-581
24. Amat S., Abrial C., Penault-Llorca F., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94 (2005) 255-263
25. Schwartz G. Neoadjuvant induction chemotherapy. Minerva Ginecol 57 (2005) 327-348
26. Hennessy B., Hortobagyi G., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 (2005) 9304-9311
27. Mamounas E. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 83 (2003) 931-934
28. Mamounas E., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 (2005) 2694-2702
29. Xing Y., Foy M., Cox D., Kuerer H., Hunt K., and Cormier J. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93 (2006) 539-546
30. Jones R., Lakhani S., Ring A., Ashley S., Walsh G., and Smith I. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94 (2006) 358-362
31. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up - Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 (1999) 47-52